Current
14.7×
5-Year Average
10.8×
All-Time High
14.9×
All-Time Low
5.8×
EV/EBITDA daily chart for Quest Diagnostics (DGX)
Jun 8, 2021 – Jun 5, 2026 · 1,255 trading days
Historical EV/EBITDA for Quest Diagnostics (DGX) from 2001 to 2025
| 2025 | $19.26B | $2.03B | 12.7× | +0.5× | |
| 2024 | $16.75B | $1.90B | 12.2× | +0.6× | |
| 2023 | $15.44B | $1.73B | 11.6× | -0.5× | |
| 2022 | $17.68B | $1.82B | 12.1× | +4.2× | |
| 2021 | $21.11B | $3.16B | 7.9× | -0.2× | |
| 2020 | $16.09B | $2.41B | 8.1× | -3.5× | |
| 2019 | $14.31B | $1.58B | 11.6× | +0.9× | |
| 2018 | $11.32B | $1.40B | 10.8× | -0.9× | |
| 2017 | $13.39B | $1.45B | 11.7× | +0.9× | |
| 2016 | $12.68B | $1.48B | 10.9× | +2.1× | |
| 2015 | $10.17B | $1.56B | 8.8× | -1.3× | |
| 2014 | $9.72B | $1.32B | 10.0× | +3.9× | |
| 2013 | $7.82B | $1.79B | 6.1× | -2.0× | |
| 2012 | $9.25B | $1.52B | 8.1× | -1.8× | |
| 2011 | $9.19B | $1.31B | 10.0× | +2.8× | |
| 2010 | $8.72B | $1.57B | 7.2× | -1.4× | |
| 2009 | $10.88B | $1.57B | 8.6× | -0.8× | |
| 2008 | $9.83B | $1.35B | 9.4× | -2.3× | |
| 2007 | $10.24B | $1.16B | 11.7× | +2.6× | |
| 2006 | $10.25B | $1.28B | 9.1× | -1.4× | |
| 2005 | $10.21B | $1.11B | 10.6× | +0.7× | |
| 2004 | $9.57B | $1.07B | 9.9× | +1.0× | |
| 2003 | $7.54B | $949.57M | 8.9× | +0.3× | |
| 2002 | $5.52B | $723.84M | 8.6× | -4.8× | |
| 2001 | $6.83B | $559.12M | 13.5× | — |
- 202512.7×
- 202412.2×
- 202311.6×
- 202212.1×
- 20217.9×
- 20208.1×
- 201911.6×
- 201810.8×
- 201711.7×
- 201610.9×
- 20158.8×
- 201410.0×
- 20136.1×
- 20128.1×
- 201110.0×
- 20107.2×
- 20098.6×
- 20089.4×
- 200711.7×
- 20069.1×
- 200510.6×
- 20049.9×
- 20038.9×
- 20028.6×
- 200113.5×
About EV/EBITDA at Quest Diagnostics (DGX)
Quest Diagnostics (DGX) EV/EBITDA ratio is 14.7× as of June 5, 2026. The 5-year average is 10.8×. The sector median currently stands at 15.0×. The current ratio is at the 99th percentile of its own 10-year history.
Quest Diagnostics (DGX) historical EV/EBITDA ratio has ranged from a low of 5.8× (2022) to a high of 14.9× (2026) in the available daily series.
The EV/EBITDA ratio (the enterprise multiple) compares enterprise value (EV) to trailing twelve-month (TTM) EBITDA. EV is calculated as market capitalisation + total debt − cash & short-term investments. Because EV/EBITDA is capital-structure-neutral and ignores non-cash depreciation and amortisation, it is the standard multiple used in M&A and for cross-company or cross-border comparisons. Note: this calculation uses a simplified EV (minority interest and preferred equity excluded due to data availability), consistent with most public financial-data providers.
Quest Diagnostics EV/EBITDA by Year
Quest Diagnostics EV/EBITDA 2025: 12.7×
Quest Diagnostics (DGX) EV/EBITDA ratio in 2025 was 12.7×, expanded from 12.2× the prior year.
Quest Diagnostics EV/EBITDA 2024: 12.2×
Quest Diagnostics (DGX) EV/EBITDA ratio in 2024 was 12.2×, expanded from 11.6× the prior year.
Quest Diagnostics EV/EBITDA 2023: 11.6×
Quest Diagnostics (DGX) EV/EBITDA ratio in 2023 was 11.6×, contracted from 12.1× the prior year.
Quest Diagnostics EV/EBITDA 2022: 12.1×
Quest Diagnostics (DGX) EV/EBITDA ratio in 2022 was 12.1×, expanded from 7.9× the prior year.
Quest Diagnostics EV/EBITDA 2021: 7.9×
Quest Diagnostics (DGX) EV/EBITDA ratio in 2021 was 7.9×.
EV is calculated as Market Cap + Total Debt − Cash & Short-Term Investments (simplified). Minority interest and preferred equity are excluded due to data availability. This is consistent with the methodology used by most public financial data providers.
Sector peers by EV/EBITDA — chart
Current ratio vs. sector peers. Highlighted bar is this company.
Sector peers by EV/EBITDA — table
Healthcare peers of Quest Diagnostics (DGX), ranked by EV/EBITDA ratio.
| 13.9× | |
| 13.6× | |
| 13.6× | |
| 13.2× | |
| 12.9× | |
| 12.9× | |
| 12.7× | |
| 12.4× | |
| 12.0× | |
| 11.7× | |
| 11.5× | |
| 11.5× | |
| 11.2× | |
| 10.5× | |
| 10.0× | |
| 8.8× | |
| 8.5× | |
| 8.2× | |
| 7.9× | |
| 7.8× | |
| 6.8× | |
| 6.5× | |
| 5.8× | |
| 5.7× | |
| 4.5× |
- 13.6×
- 13.2×
- 12.9×
- 12.4×
- 12.0×
- 11.7×
- 11.5×
- 10.5×
- 10.0×
- 8.5×
- 8.2×
- 7.9×
- 7.8×
- 5.8×
- 4.5×
Frequently asked questions
Quest Diagnostics (DGX) Key Financials
Charts, filings, and peer comparison for every metric